Immunotherapy combo shows promise against tough rectal cancers
NCT ID NCT06770270
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether adding the immunotherapy drug pucotenlimab to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer. About 68 participants will receive the combination, and doctors will check if the tumor disappears completely. If it works, some patients might avoid surgery altogether.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pucotenlimab (an immunotherapy drug) combined with chemotherapy and radiation
What this could lead to
If successful, this combination could help more patients with locally advanced rectal cancer achieve a complete response, potentially avoiding surgery and reducing the risk of recurrence.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 68 participants, so results may not apply to all patients. Immunotherapy can cause immune-related side effects, and the added benefit over standard treatment is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital Of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••